Cost-Minimization Analysis of Two Drug Therapy Projects Including Traditional Chinese Medicines and Chemical Medicines in BPH Patients
January 2006
in “
Zhongguo yaofang
”
TLDR Qianliekang and liuweidihuangwan are cheaper for BPH treatment than finasteride and tamsulosin.
The study conducted a cost-effectiveness analysis of two drug therapy regimens for benign prostatic hyperplasia (BPH) involving 60 patients. Group A received finasteride and tamsulosin, while Group B was treated with qianliekang and liuweidihuangwan. The therapeutic efficacy and adverse drug reactions (ADRs) were similar between the two groups, with no significant differences observed. However, the cost of treatment for Group A was 1,562.10 yuan, significantly higher than the 233.25 yuan for Group B. The study concluded that the combination of qianliekang and liuweidihuangwan was the more economical therapy for BPH.